CY1112527T1 - Συνθεσεις που περιεχουν αμιοdαrονε και sulfoalkyl ether cyclodextrin - Google Patents
Συνθεσεις που περιεχουν αμιοdαrονε και sulfoalkyl ether cyclodextrinInfo
- Publication number
- CY1112527T1 CY1112527T1 CY20121100190T CY121100190T CY1112527T1 CY 1112527 T1 CY1112527 T1 CY 1112527T1 CY 20121100190 T CY20121100190 T CY 20121100190T CY 121100190 T CY121100190 T CY 121100190T CY 1112527 T1 CY1112527 T1 CY 1112527T1
- Authority
- CY
- Cyprus
- Prior art keywords
- amiodarone
- cyclodextrin
- compositions
- sulfoalkyl ether
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title abstract 6
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 title abstract 6
- 229960005260 amiodarone Drugs 0.000 title abstract 6
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 5
- 239000007788 liquid Substances 0.000 abstract 4
- 239000000243 solution Substances 0.000 abstract 2
- 125000004964 sulfoalkyl group Chemical group 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 239000003416 antiarrhythmic agent Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000012895 dilution Substances 0.000 abstract 1
- 238000010790 dilution Methods 0.000 abstract 1
- 239000012153 distilled water Substances 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/139,620 US6869939B2 (en) | 2002-05-04 | 2002-05-04 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| EP03728598A EP1501496B1 (en) | 2002-05-04 | 2003-04-29 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1112527T1 true CY1112527T1 (el) | 2015-12-09 |
Family
ID=29399340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100190T CY1112527T1 (el) | 2002-05-04 | 2012-02-23 | Συνθεσεις που περιεχουν αμιοdαrονε και sulfoalkyl ether cyclodextrin |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6869939B2 (enExample) |
| EP (2) | EP1501496B1 (enExample) |
| JP (2) | JP4764004B2 (enExample) |
| KR (1) | KR100984197B1 (enExample) |
| AT (1) | ATE535239T1 (enExample) |
| AU (1) | AU2003234285B2 (enExample) |
| CA (1) | CA2483774C (enExample) |
| CY (1) | CY1112527T1 (enExample) |
| DK (2) | DK2402008T3 (enExample) |
| ES (2) | ES2378306T3 (enExample) |
| HU (1) | HUE027551T2 (enExample) |
| IL (2) | IL165022A0 (enExample) |
| MX (1) | MXPA04010925A (enExample) |
| PT (1) | PT1501496E (enExample) |
| SI (2) | SI1501496T1 (enExample) |
| WO (1) | WO2003092590A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1713504B1 (en) | 2004-01-30 | 2017-06-07 | Zoetis Services LLC | Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms |
| BRPI0510119A (pt) | 2004-04-23 | 2007-09-25 | Cydex Inc | formulação para dpi contendo sulfoaquil éter de ciclodextrina |
| EP1766037B1 (en) | 2004-05-12 | 2015-07-01 | Transworld Technologies Limited | Generation of hydrogen from hydrocarbon-bearing materials |
| US7426960B2 (en) | 2005-05-03 | 2008-09-23 | Luca Technologies, Inc. | Biogenic fuel gas generation in geologic hydrocarbon deposits |
| US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| US7416879B2 (en) | 2006-01-11 | 2008-08-26 | Luca Technologies, Inc. | Thermacetogenium phaeum consortium for the production of materials with enhanced hydrogen content |
| KR20160033796A (ko) | 2006-03-28 | 2016-03-28 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
| KR20090010953A (ko) * | 2006-03-28 | 2009-01-30 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형 |
| US7977282B2 (en) | 2006-04-05 | 2011-07-12 | Luca Technologies, Inc. | Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material |
| US7696132B2 (en) | 2006-04-05 | 2010-04-13 | Luca Technologies, Inc. | Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material |
| DK2061458T3 (en) * | 2006-09-15 | 2015-03-09 | Univ Minnesota | Topiramate compositions and methods for their use |
| US20090239942A1 (en) * | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
| US20090270496A1 (en) * | 2007-05-03 | 2009-10-29 | Courchesne William E | Antifungal compounds |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| US8479813B2 (en) | 2009-12-16 | 2013-07-09 | Luca Technologies, Inc. | Biogenic fuel gas generation in geologic hydrocarbon deposits |
| EP2335686A1 (en) | 2009-12-21 | 2011-06-22 | LEK Pharmaceuticals d.d. | An aqueous intravenous nanosuspension with reduced adverse effects |
| NL2004260C2 (en) * | 2010-02-18 | 2011-08-22 | Univ Amsterdam | Disinfectant composition and its use in dental treatment. |
| PH12012502454A1 (en) * | 2010-06-11 | 2013-02-18 | Baxter Healthcare Sa | Formulations including amiodarone and salts thereof and methods of their manufacture and use |
| ES2646226T3 (es) | 2011-07-20 | 2017-12-12 | Hospira, Inc. | Composiciones que comprenden diclofenaco para el tratamiento del dolor posoperatorio |
| CA2852716C (en) | 2011-11-29 | 2015-11-17 | Jurox Pty Ltd | Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug |
| CA2861077A1 (en) * | 2012-01-30 | 2013-08-08 | Baxter International Inc. | Non-anticoagulant sulfated or sulfonated polysaccharides |
| PT3702374T (pt) | 2012-02-15 | 2022-06-23 | Cydex Pharmaceuticals Inc | Processo de fabrico para derivados de ciclodextrina |
| CN110066351B (zh) | 2012-02-28 | 2022-06-14 | 锡德克斯药物公司 | 烷基化环糊精组合物及其制备和使用方法 |
| US9004162B2 (en) | 2012-03-23 | 2015-04-14 | Transworld Technologies Inc. | Methods of stimulating acetoclastic methanogenesis in subterranean deposits of carbonaceous material |
| JP2015534970A (ja) * | 2012-10-17 | 2015-12-07 | ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ | 多発性骨髄腫の治療のためのアントシアニジン複合体 |
| JP6557144B2 (ja) | 2012-10-22 | 2019-08-07 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法 |
| WO2014075935A1 (de) * | 2012-11-15 | 2014-05-22 | Sapiotec Gmbh | Delphinidinkomplex als antiphlogistischer oder immunsuppressiver wirkstoff |
| EP2773033B1 (en) | 2013-02-28 | 2018-12-05 | Dialog Semiconductor GmbH | Divide by 2 and 3 charge pump methods |
| GB201312737D0 (en) | 2013-07-17 | 2013-08-28 | Univ Greenwich | Cyclodextrin |
| FI3183295T3 (fi) | 2014-08-22 | 2023-09-25 | Cydex Pharmaceuticals Inc | Fraktioidut alkyloidut syklodekstriinikoostumukset ja menetelmät niiden valmistamiseksi ja käyttämiseksi |
| US10736891B2 (en) | 2016-01-07 | 2020-08-11 | Roy MADIGAN | Composition and method for treating chagas disease |
| WO2017149552A1 (en) * | 2016-03-04 | 2017-09-08 | Sun Pharmaceutical Industries Ltd. | Parenteral dosage form of amiodarone |
| CN107753439A (zh) * | 2016-08-22 | 2018-03-06 | 黑龙江迪龙制药有限公司 | 一种注射用盐酸胺碘酮及其制备方法 |
| TW201828938A (zh) | 2016-11-18 | 2018-08-16 | 德商艾庫里斯抗感染治療有限公司 | 以改質的環糊精及酸化劑為基底之經脒取代之β-內醯胺化合物的新穎調配物，其製備方法及作為抗微生物醫藥組合物之用途 |
| US12416024B2 (en) | 2018-03-29 | 2025-09-16 | Transworld Technologies Inc. | Biologically enhanced oil recovery methods |
| US10973780B2 (en) * | 2019-05-15 | 2021-04-13 | Bexson Biomedical, Inc. | Ketamine formulation for subcutaneous injection |
| EP4010031A1 (en) | 2019-08-06 | 2022-06-15 | L.E.A.F Holdings Group LLC | Processes of preparing polyglutamated antifolates and uses of their compositions |
| JP2023551145A (ja) | 2020-11-18 | 2023-12-07 | ベクソン バイオメディカル，インク． | 医薬化合物の錯化剤塩製剤 |
| CN115969833A (zh) * | 2023-01-03 | 2023-04-18 | 上海上药第一生化药业有限公司 | 胺碘酮药物组合物、注射液及其制备方法及含其的注射器 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0491812A4 (en) | 1989-09-14 | 1992-11-04 | Australian Commercial Research & Development Limited | Drug delivery compositions |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| EP0518930A4 (en) | 1990-03-02 | 1993-09-15 | Australian Commercial Research & Development Limited | Cyclodextrin compositions and methods for pharmaceutical and industrial applications |
| US5234949A (en) | 1992-04-01 | 1993-08-10 | Academic Pharmaceuticals, Inc. | Parenteral solutions containing amiodarone in acetate buffer solution |
| FR2735978B1 (fr) | 1995-06-30 | 1997-09-19 | Sanofi Sa | Composition pharmaceutique d'amiodarone pour administration parenterale |
| UA57734C2 (uk) * | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
| US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US5874418A (en) * | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| TR200102109T2 (tr) | 1999-01-21 | 2001-12-21 | Bristol-Myers Squibb Company | Ras-farnesiltransferazı inhibitörü ve sülfobütileter-7-ß-siklodekstrin veya 2-hidroksipropil-ß-siklodekstrin kompleksi ve metod. |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| GB9921958D0 (en) * | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins |
| US6479541B1 (en) * | 2000-03-30 | 2002-11-12 | Baxter International | Amiodarone-containing parenteral administration |
-
2002
- 2002-05-04 US US10/139,620 patent/US6869939B2/en not_active Expired - Lifetime
-
2003
- 2003-04-29 CA CA2483774A patent/CA2483774C/en not_active Expired - Lifetime
- 2003-04-29 EP EP03728598A patent/EP1501496B1/en not_active Expired - Lifetime
- 2003-04-29 SI SI200332113T patent/SI1501496T1/sl unknown
- 2003-04-29 SI SI200332474A patent/SI2402008T1/sl unknown
- 2003-04-29 AU AU2003234285A patent/AU2003234285B2/en not_active Expired
- 2003-04-29 KR KR1020047017639A patent/KR100984197B1/ko not_active Expired - Lifetime
- 2003-04-29 IL IL16502203A patent/IL165022A0/xx unknown
- 2003-04-29 EP EP11182697.0A patent/EP2402008B1/en not_active Expired - Lifetime
- 2003-04-29 DK DK11182697.0T patent/DK2402008T3/en active
- 2003-04-29 DK DK03728598.8T patent/DK1501496T3/da active
- 2003-04-29 ES ES03728598T patent/ES2378306T3/es not_active Expired - Lifetime
- 2003-04-29 AT AT03728598T patent/ATE535239T1/de active
- 2003-04-29 JP JP2004500775A patent/JP4764004B2/ja not_active Expired - Lifetime
- 2003-04-29 HU HUE11182697A patent/HUE027551T2/en unknown
- 2003-04-29 PT PT03728598T patent/PT1501496E/pt unknown
- 2003-04-29 MX MXPA04010925A patent/MXPA04010925A/es active IP Right Grant
- 2003-04-29 ES ES11182697.0T patent/ES2567716T3/es not_active Expired - Lifetime
- 2003-04-29 WO PCT/US2003/013250 patent/WO2003092590A2/en not_active Ceased
-
2004
- 2004-11-04 IL IL165022A patent/IL165022A/en active IP Right Grant
-
2011
- 2011-03-07 JP JP2011048873A patent/JP5656692B2/ja not_active Expired - Lifetime
-
2012
- 2012-02-23 CY CY20121100190T patent/CY1112527T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI1501496T1 (sl) | 2012-04-30 |
| AU2003234285A1 (en) | 2003-11-17 |
| ATE535239T1 (de) | 2011-12-15 |
| US6869939B2 (en) | 2005-03-22 |
| EP1501496B1 (en) | 2011-11-30 |
| DK1501496T3 (da) | 2012-03-19 |
| EP2402008B1 (en) | 2016-01-27 |
| HUE027551T2 (en) | 2016-10-28 |
| IL165022A (en) | 2011-08-31 |
| JP2005530744A (ja) | 2005-10-13 |
| CA2483774A1 (en) | 2003-11-13 |
| EP2402008A1 (en) | 2012-01-04 |
| DK2402008T3 (en) | 2016-05-02 |
| US20030216353A1 (en) | 2003-11-20 |
| KR20040106452A (ko) | 2004-12-17 |
| JP2011116776A (ja) | 2011-06-16 |
| EP1501496A4 (en) | 2006-05-31 |
| ES2378306T3 (es) | 2012-04-11 |
| SI2402008T1 (sl) | 2016-05-31 |
| WO2003092590A3 (en) | 2004-01-22 |
| WO2003092590A2 (en) | 2003-11-13 |
| PT1501496E (pt) | 2012-02-20 |
| IL165022A0 (en) | 2005-12-18 |
| ES2567716T3 (es) | 2016-04-26 |
| AU2003234285B2 (en) | 2007-01-04 |
| EP1501496A2 (en) | 2005-02-02 |
| JP5656692B2 (ja) | 2015-01-21 |
| CA2483774C (en) | 2011-07-19 |
| KR100984197B1 (ko) | 2010-09-28 |
| MXPA04010925A (es) | 2005-02-14 |
| JP4764004B2 (ja) | 2011-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112527T1 (el) | Συνθεσεις που περιεχουν αμιοdαrονε και sulfoalkyl ether cyclodextrin | |
| AR037755A1 (es) | Composiciones acuosas con contenido de metronidazol | |
| CY1107506T1 (el) | Μεθοδος για σταθεροποιηση ενωσεων βενζιμιδαζολης | |
| CY1114631T1 (el) | Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο | |
| BR0209862A (pt) | Imunoconjugados de anticorpos de cd44 citotóxicos | |
| BR0215266A (pt) | Preparação liofilizada compreendendo anticorpos contra o receptor de egf | |
| TR199802231T2 (xx) | Ayr�k halkal� aril bile�i�i tuzlar�n�n inkl�zyon kompleksleri. | |
| DE60019693D1 (de) | Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten | |
| CO5140077A1 (es) | Complejo estable insoluble en agua, composiciones farma- ceuticas que lo contienen y metodos para su preparacion . . | |
| DK1056477T3 (da) | Naopartikler omfattende polyisobutylcyanoacrylat og cyclodextriner | |
| ITRM20010464A1 (it) | Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica. | |
| BR0006009A (pt) | Compostos organofosforosos para composições dentais polimerizáveis | |
| ATE274913T1 (de) | Wässerige zusammensetzung enthaltend amphotericin b | |
| CY1113461T1 (el) | Μη συνεζευγμενο χολικο οξυ μαζι με propyl gallate και/ή βηα για την αυξηση της απορροφησης μακρο-μοριων | |
| BG107347A (bg) | Висококонцентрирани стабилни разтвори на мелоксикам | |
| TR200001906T2 (tr) | Koks-Inhibitörleri olarak 2,3-ikameli indol bileşikleri. | |
| EA200300406A1 (ru) | Фармацевтическая композиция дронедарона для парентерального введения | |
| MY135548A (en) | Aqueous preparation containing oligopeptides and etherified cyclodextrin | |
| ES2194279T3 (es) | Composiciones de ciclodextrina que contienen un derivado de avermectina o de milbemicina. | |
| ATE317695T1 (de) | Parenterale lösung enthaltend amiodaron | |
| MX2022010884A (es) | Agentes terapéuticos y conjugados de estos. | |
| TR200101493T2 (tr) | Eletriptan hidrobromid monohidrat | |
| NZ512270A (en) | Soluble compositions of triphenylethylene antiestrogens | |
| CY1105345T1 (el) | Φαινυλαλκινια | |
| GB9901253D0 (en) | Bis-terpyridine-platinum(II) complexes |